+308.2%
MRVL vs GSK
+53.4%
+254.7%
-60.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.8% | -2.7% | +3.5% | +0.5% |
| 7D | +7.1% | -4.2% | +11.3% | +6.6% |
| 30D | +3.1% | -7.5% | +10.6% | +2.1% |
| 3M | -21.9% | -3.3% | -18.7% | -22.2% |
| 6M | +151.8% | -9.3% | +161.2% | +150.5% |
| YTD | +165.6% | +1.6% | +164.0% | +167.4% |
| 1Y | +242.3% | +25.5% | +216.8% | +251.6% |
| 3Y | +308.2% | +49.3% | +258.9% | +342.7% |
| All | +308.2% | +53.4% | +254.7% | +342.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling